Charles Newell, MD
Ophthalmology · Tallahassee, FLNPI 1245298223
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $28,154 of the $29,570 with a category attached, or 95.2%. US Retina LLC accounts for 95.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $12,120 and has fallen 96.6% since, to $416 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $462.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$28K
- Genentech USA, Inc.$306
- AbbVie$175
- Regeneron Healthcare Solutions, Inc.$171
- Genentech, Inc.$154
- Harrow Eye, LLC$146
- plus $465 from 9 others
Across 33 payments — averaging $22,737 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$720K
- Apellis Pharmaceuticals, Inc.$30K
What the payments were for
- Food & beverage$1,4175%
- Ownership interest$28,15495%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $28,154 |
| Genentech USA, Inc. | 16 | $306 |
| AbbVie(2 entities) | 9 | $175 |
| Regeneron Healthcare Solutions, Inc. | 8 | $171 |
| Genentech, Inc. | 1 | $154 |
| Harrow Eye, LLC | 3 | $146 |
| Apellis Pharmaceuticals, Inc. | 6 | $138 |
| Astellas Pharma US Inc | 3 | $71 |
| Dendreon Pharmaceuticals LLC | 2 | $60 |
| Alcon | 3 | $59 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Novartis | 2 | $27 |
| Sandoz | 1 | $26 |
| Olympus America Inc. | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$154
- TRIESENCE$111
How this compares
$29,570 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 198 | $8,906 |
| Ketorolac Tromethamine | 55 | $1,488 |
| MoxifloxacinMoxifloxacin Hcl | 16 | $934 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 85 | $630 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Tallahassee
- Harold BrooksTallahassee$683K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.